Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Read more about Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Read more about Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel Read more about Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes Read more about Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes
Study of IMPT-314 in R/R Aggressive B-cell NHL Read more about Study of IMPT-314 in R/R Aggressive B-cell NHL
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Read more about A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Read more about Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Read more about PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) Read more about A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TA Read more about A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TA